AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (≥50% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06758401

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:29:08.102396+00:00

Published At

2026-04-20T00:00:00+00:00

Record Updated At

2026-04-20

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Non-Small Cell Lung Cancer", "Carcinoma, Non-Small-Cell Lung", "Carcinoma, Non-Small-Cell Lung (NSCLC)"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-04-20"

protocolSection.identificationModule.nctId

"NCT06758401"

protocolSection.identificationModule.officialTitle

"AN OPEN-LABEL, RANDOMIZED, CONTROLLED PHASE 3 STUDY OF SIGVOTATUG VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB COMPARED WITH PEMBROLIZUMAB MONOTHERAPY AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH PD-L1 HIGH (\u226550% OF TUMOR CELLS EXPRESSING PD-L1), LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC NON-SMALL CELL LUNG CANCER (BE6A LUNG-02)"

protocolSection.statusModule.overallStatus

"RECRUITING"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Non-Small Cell Lung Cancer (protocolSection.conditionsModule.conditions)
• Carcinoma, Non-Small-Cell Lung (protocolSection.conditionsModule.conditions)
• Carcinoma, Non-Small-Cell Lung (NSCLC) (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.